| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3274413 | Médecine des Maladies Métaboliques | 2014 | 8 Pages |
Abstract
The addition of each DPP-4 inhibitor significantly reduced glycemic variability with no difference between the two drugs. However, vildagliptin was associated with better circadian glycemic control than sitagliptin and with a significant decrease in overall hyperglycemia, mainly driven by a reduction in basal hyperglycemia.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
L. Monnier, S. Dejager, P. Serusclat, C. Petit, P. Valensi, D. Huet, D. Raccah, C. Colette, S. Quéré, B. Guerci,